LLY vs. QGEN: Eli Lilly vs. Qiagen Stock Comparison

Company Profile

Eli Lilly (LLY) and Qiagen (QGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but LLY is classified in Pharmaceuticals while QGEN is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Eli Lilly (LLY) at 86.02% and Qiagen (QGEN) at 10.81% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Eli Lilly (LLY) at 31.90% and Qiagen (QGEN) at 18.20% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Eli Lilly (LLY) at 53.66% and Qiagen (QGEN) at 27.75% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Eli Lilly (LLY) at 44.70% and Qiagen (QGEN) at 5.65% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both companies show strong earnings momentum, but Qiagen (QGEN) at 409.76% is the standout with EPS growth above its industry range; Eli Lilly (LLY) at 95.99% also sits in the top quartile.

Growth Metrics

Financial Strength

Qiagen (QGEN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Eli Lilly (LLY) at 1.39 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for LLY.

Qiagen (QGEN) at 0.47 carries an industry-typical debt-to-equity mix, while Eli Lilly (LLY) at 1.23 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Both Eli Lilly (LLY) at 0.49% and Qiagen (QGEN) at 0.71% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Eli Lilly (LLY) at 21.71% and Qiagen (QGEN) at 18.21% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

Qiagen (QGEN) at 27.21 is near its industry’s usual P/E ratio, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — LLY needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Eli Lilly (LLY) at 13.95 and Qiagen (QGEN) at 4.91 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Qiagen (QGEN) at 2.99 sits near its industry’s typical P/B ratio, while Eli Lilly (LLY) at 29.96 prices above its benchmark range — LLY looks rich relative to book.

Valuation Metrics